Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Recent progress has been made in the identification and implementation of best transfusion practices on the basis of evidence-based clinical trials, published clinical practice guidelines, and process improvements for blood use and clinical patient outcomes. However, substantial variability persists in transfusion outcomes for patients in some clinical settings--eg, patients undergoing cardiothoracic surgery. This variability could be the result of insufficient understanding of published guidelines; different recommendations of medical societies, including the specification of a haemoglobin concentration threshold to use as a transfusion trigger; the value of haemoglobin as a surrogate indicator for transfusion benefit, even though only changes in concentration and not absolute red cell mass of haemoglobin can be identified; and disagreement about the validity of the level 1 evidence for clinical practice guidelines. Nevertheless, institutional experience and national databases suggest that a restrictive blood transfusion approach is being increasingly implemented as best practice.

Original publication

DOI

10.1016/S0140-6736(13)60650-9

Type

Journal article

Journal

Lancet

Publication Date

25/05/2013

Volume

381

Pages

1845 - 1854

Keywords

Adult, Blood Transfusion, Cardiovascular Diseases, Erythrocyte Transfusion, Evidence-Based Medicine, Guideline Adherence, Hemoglobins, Humans, Postoperative Complications, Practice Guidelines as Topic, Professional Practice, Randomized Controlled Trials as Topic, Transfusion Reaction